PRKCZ Rabbit Polyclonal Antibody

CAT#: TA385054

PKC zeta Rabbit polyclonal Antibody

Product Images

Western Blot analysis of various cells using PKC ζ Polyclonal Antibody diluted at 1：2000

• 

  Western Blot analysis of COS7 cells using PKC ζ Polyclonal Antibody diluted at 1：2000

• 

  Immunofluorescence analysis of NIH/3T3 cells, using PKC zeta Antibody. The picture on the right is blocked with the synthesized peptide.

• 

  Immunohistochemistry analysis of paraffin-embedded human brain tissue, using PKC zeta Antibody. The picture on the right is blocked with the synthesized peptide.

• 

  Western blot analysis of lysates from COS7 cells, treated with PMA 125ng/ml 30', using PKC zeta Antibody. The lane on the right is blocked with the synthesized peptide.

Show all 5 images

Specifications

Product Data

• Applications: ELISA, IF, IHC, WB
• Recommended Dilution: WB: 1/500-1/2000
  IHC: 1/100-1/300
  IF: 1/200-1/1000
  ELISA: 1/5000
• Reactivities: Human, Monkey, Mouse, Rat
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: The antiserum was produced against synthesized peptide derived from human PKC zeta. AA range:526-575
• Formulation: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide, pH 7.3.
• Concentration: lot specific
• Purification: Affinity Chromatography
• Conjugation: Unconjugated
• Storage: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
• Stability: 1 year
• Predicted Protein Size: Observed MW (kDa):80
• Database Link:
  UniProt ID Q05513
• Background: Swiss-Prot Acc.Q05513.Calcium- and diacylglycerol-independent serine/threonine-protein kinase that functions in phosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activated protein (MAP) kinase cascade, and is involved in NF-kappa-B activation, mitogenic signaling, cell proliferation, cell polarity, inflammatory response and maintenance of long-term potentiation (LTP). Upon lipopolysaccharide (LPS) treatment in macrophages, or following mitogenic stimuli, functions downstream of PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascade independently of RAF1 activation. Required for insulin-dependent activation of AKT3, but may function as an adapter rather than a direct activator. Upon insulin treatment may act as a downstream effector of PI3K and contribute to the activation of translocation of the glucose transporter SLC2A4/GLUT4 and subsequent glucose transport in adipocytes. In EGF-induced cells, binds and activates MAP2K5/MEK5-MAPK7/ERK5 independently of its kinase activity and can activate JUN promoter through MEF2C. Through binding with SQSTM1/p62, functions in interleukin-1 signaling and activation of NF-kappa-B with the specific adapters RIPK1 and TRAF6. Participates in TNF-dependent transactivation of NF-kappa-B by phosphorylating and activating IKBKB kinase, which in turn leads to the degradation of NF-kappa-B inhibitors. In migrating astrocytes, forms a cytoplasmic complex with PARD6A and is recruited by CDC42 to function in the establishment of cell polarity along with the microtubule motor and dynein. In association with FEZ1, stimulates neuronal differentiation in PC12 cells. In the inflammatory response, is required for the T-helper 2 (Th2) differentiation process, including interleukin production, efficient activation of JAK1 and the subsequent phosphorylation and nuclear translocation of STAT6. May be involved in development of allergic airway inflammation (asthma), a process dependent on Th2 immune response. In the NF-kappa-B-mediated inflammatory response, can relieve SETD6-dependent repression of NF-kappa-B target genes by phosphorylating the RELA subunit at 'Ser-311'. In vein endothelial cells treated with the oxidant peroxynitrite, phosphorylates STK11 leading to nuclear export of STK11, subsequent inhibition of PI3K/Akt signaling, and increased apoptosis. Phosphorylates VAMP2 in vitro (PubMed:17313651).